翁劍蓉++++++繆+懿++++++孫云燕
[摘要] 目的 檢測(cè)UNR基因在上皮性卵巢癌細(xì)胞中的表達(dá),并觀察其對(duì)卵巢癌細(xì)胞上皮間質(zhì)轉(zhuǎn)化(EMT)的影響。 方法 采用實(shí)時(shí)熒光定量PCR(qPCR)檢測(cè)并比較體外培養(yǎng)的人上皮性卵巢癌細(xì)胞系SKOV-3、HO-8910、ES-2和永生化人卵巢上皮細(xì)胞系MOODY中UNR基因的表達(dá),采用qPCR和Western blot檢測(cè)卵巢癌SKOV-3細(xì)胞的UNR-RNAi干擾效率,應(yīng)用Transwell侵襲小室實(shí)驗(yàn)檢測(cè)SKOV-3細(xì)胞的侵襲能力,采用Western blot檢測(cè)SKOV-3細(xì)胞E-cadherin的蛋白表達(dá)。 結(jié)果 UNR在上皮性卵巢癌細(xì)胞系SKOV-3、HO-8910、ES-2中均有顯著表達(dá)。shUNR轉(zhuǎn)染SKOV-3后,Transwell侵襲小室實(shí)驗(yàn)顯示,UNR-RNAi組穿膜細(xì)胞數(shù)為每視野(29.33±5.14)個(gè),顯著低于陰性對(duì)照組(76.00±5.42)個(gè)(P < 0.01)。此外,Western blot顯示UNR基因干擾后SKOV-3細(xì)胞中E-cadherin的蛋白表達(dá)顯著上調(diào)。 結(jié)論 shUNR可以抑制卵巢癌SKOV-3細(xì)胞UNR基因的表達(dá),降低卵巢癌細(xì)胞的侵襲能力。干擾后E-cadherin的表達(dá)上調(diào)提示UNR可能促進(jìn)卵巢癌EMT的發(fā)生,以UNR基因?yàn)榘悬c(diǎn)的干擾技術(shù)有望成為卵巢癌治療的新策略。
[關(guān)鍵詞] RNA干擾;卵巢癌;UNR;上皮間質(zhì)轉(zhuǎn)化
[中圖分類號(hào)] R737.3 [文獻(xiàn)標(biāo)識(shí)碼] A [文章編號(hào)] 1673-7210(2017)10(c)-0021-05
Role of UNR in regulating the epithelial mesenchymal transition of epithelial ovarian cancer cells
WENG Jianrong MIAO Yi SUN Yunyan
Department of Gynecology and Obstetrics, the First People′s Hospital Affiliated to Shanghai Jiao Tong University, Shanghai 200080, China
[Abstract] Objective To detect the expression of UNR gene in epithelial ovarian cancer cells, and to observe the effect of UNR gene on epithelial mesenchymal transition (EMT) of ovarian cancer cells. Methods Real-time quantitative PCR (qPCR) was used to detect and compare the expression of UNR gene in human epithelial ovarian cancer cell lines SKOV-3, HO-8910, ES-2 and immortalized human ovarian epithelial cell lines MOODY in vitro. qPCR and Western blot were used to detect the UNR-RNAi interfering efficiency of ovarian cancer cell SKOV-3, the invasion ability of SKOV-3 cells was detected by Transwell invasion assay. The protein expression of E-cadherin in SKOV-3 cells was detected by Western blot. Results UNR was significantly expressed in the epithelial ovarian cancer cell lines SKOV-3, HO-8910 and ES-2. After SKOV-3 was transfected by shUNR, Transwell assay showed that the number of transmembrane cells in UNR-RNAi group was (29.33±5.14) per field, which was significantly lower than that in negative control group [(76.00±5.42) per field] (P < 0.01). In addition, Western blot showed that the expression of E-cadherin protein in SKOV-3 cells was significantly up-regulated after UNR gene interference. Conclusion shUNR can markedly inhibit the expression of UNR gene in ovarian cancer SKOV-3 cells, decrease the invasive ability of ovarian cancer cells. The up-regulated expression of E-cadherin after interference shows that UNR may promote the occurrence of ovarian cancer EMT, thus, the interfering technology taking UNR gene as target is expected to become a new strategy for the treatment of ovarian cancer.endprint
[Key words] RNA interference; Ovarian cancer; UNR; Epithelial mesenchymal transition
卵巢癌是婦科常見(jiàn)的惡性腫瘤,起病隱匿,易轉(zhuǎn)移復(fù)發(fā),5年生存率僅為30%。上皮間質(zhì)轉(zhuǎn)化(EMT)是影響卵巢癌發(fā)生發(fā)展的重要因素,所以探討卵巢癌EMT的相關(guān)機(jī)制有著重要的臨床意義。本研究所研究的UNR/CSDE1(upstream of N-ras)基因是冷休克蛋白家族的成員之一,是由5個(gè)冷休克結(jié)構(gòu)域(cold-shock domains,CSDs)組成的單鏈核苷酸結(jié)合蛋白,在哺乳動(dòng)物中位于N-ras基因的上游130~150個(gè)核苷酸距離處[1],UNR既可以促進(jìn)也可以抑制轉(zhuǎn)錄[2]。Wurth等[3]研究發(fā)現(xiàn)UNR在黑色素瘤細(xì)胞里表達(dá)豐富,是RNA上游調(diào)節(jié)子,能促進(jìn)黑色素瘤細(xì)胞的侵襲和轉(zhuǎn)移。本研究通過(guò)探討UNR基因在上皮性卵巢癌中與EMT的關(guān)系,以期闡明UNR基因在卵巢癌侵襲轉(zhuǎn)移中的作用機(jī)制,旨在為卵巢癌的診斷和治療提供新的研究方向。
1 材料與方法
1.1 細(xì)胞系
人類上皮性卵巢癌細(xì)胞系SKOV-3、HO-8910、ES-2和永生化人卵巢上皮細(xì)胞系MOODY:由上海交通大學(xué)附屬第一人民醫(yī)院婦產(chǎn)科實(shí)驗(yàn)中心提供。
1.2 shRNA
UNR-RNAi慢病毒重組顆粒購(gòu)自上海吉?jiǎng)P基因化學(xué)技術(shù)有限公司。UNR-RNAi根據(jù)基因庫(kù)NCBI中人UNR/CSDE1 mRNA序列(NM_001007553.2、NM_ 001 130523.2、NM_001242891.1、NM_001242892.1、NM_ 001242893.1、NM_007158.5)設(shè)計(jì)一對(duì)特異性的小分子干擾片段,UNR-RNAi基因序列:5′-GAGATGATGTTGAATTTGACTCGAGCTCGAGTCAAATTCAACAT?鄄CATCTC-3′。陰性對(duì)照siRNA序列:5′-TTCTCCGA?鄄ACGTGTCACGT-3′。
1.3 試劑
FBS購(gòu)自上海微科生化試劑有限公司;DMEM培養(yǎng)基購(gòu)自美國(guó)Hyclone公司;TRIzol購(gòu)自上海普飛公司;Promega M-MLV試劑盒購(gòu)自美國(guó)Promega公司;SYBR Master Mixture購(gòu)自日本TAKARA公司;病毒感染試劑ENi.S.和Polybrene購(gòu)自上海吉?jiǎng)P基因化學(xué)技術(shù)有限公司;兔抗人UNR抗體和兔抗人E-鈣黏素(E-cadherin)抗體購(gòu)自英國(guó)Abcam公司;辣根過(guò)氧化物酶(HBP)標(biāo)記的抗兔二抗IgG購(gòu)自美國(guó)Santa Cruz公司;人工基底膜基質(zhì)凝膠Martrigel和Transwell小室購(gòu)自美國(guó)Corning公司。
1.4 方法
1.4.1 qPCR檢測(cè)各卵巢癌細(xì)胞系中UNR mRNA的表達(dá) 各卵巢癌細(xì)胞和MOODY細(xì)胞置于含有10%FBS的DMEM培養(yǎng)液中,于37℃、5%CO2條件下培養(yǎng),取對(duì)數(shù)生長(zhǎng)細(xì)胞進(jìn)行實(shí)驗(yàn)。收集細(xì)胞,按TRIzol試劑盒說(shuō)明書抽提細(xì)胞總RNA,取2.0 μg總RNA反轉(zhuǎn)錄成cDNA。UNR基因引物序列:上游:5′GAAGATGTCGA?鄄AGGGAACG3′,下游:5′GCGAGCACTTACAGCACCA3′;內(nèi)參基因磷酸甘油醛脫氫酶GAPDH引物序列:上游:5′TGACTTCAACAGCGACACCCA3′,下游:5′CACCCTGTTGCTGTAGCCAAA3′,以此為模板進(jìn)行PCR擴(kuò)增。采用12 μL反應(yīng)體系:SYBR Premix Ex Tap 6 μL,上下游引物(5 μmol/L)各0.5 μL,模板1.0 μL,RNase-Free H2O 4.0 μL。反應(yīng)條件:95℃預(yù)變性30 s,95℃變性5 s,60℃退火延伸30 s,40個(gè)循環(huán)。實(shí)驗(yàn)所獲得的數(shù)據(jù)采用Ct值(2-ΔΔCt法)進(jìn)行相對(duì)定量分析。
1.4.2 shUNR重組慢病毒顆粒感染卵巢癌細(xì)胞系SKOV-3 選取表達(dá)最豐富的SKOV-3細(xì)胞作為目的細(xì)胞,取對(duì)數(shù)生長(zhǎng)期細(xì)胞進(jìn)行實(shí)驗(yàn),細(xì)胞密度約80%匯合時(shí)應(yīng)用病毒感染試劑ENi.S.和Polybrene轉(zhuǎn)染shRNA。分組如下:①干擾組(UNR-RNAi組):感染了UNR-RNAi;②陰性對(duì)照組(NC組):感染了陰性對(duì)照siRNA。感染后72 h收集細(xì)胞,同時(shí)熒光顯微鏡觀察細(xì)胞病毒感染情況并予拍照,熒光率即為陽(yáng)性感染率。
1.4.3 檢測(cè)卵巢癌SKOV-3細(xì)胞的UNR-RNAi干擾效率 qPCR檢測(cè)方法同“1.4.1”。Western blot檢測(cè)如下:提取各組細(xì)胞總蛋白,蛋白定量后,采用10% SDS-PAGE凝膠電泳分離蛋白,將凝膠上的蛋白質(zhì)轉(zhuǎn)移至PVDF膜上,封閉2 h后加入相應(yīng)的一抗和二抗,反應(yīng)、洗膜、ECL曝光、顯影、洗片、拍照。以GAPDH為內(nèi)參照。
1.4.4 Transwell侵襲小室實(shí)驗(yàn)檢測(cè)侵襲能力的變化 在Transwell上室鋪Martrigel 60 μL。收集三組對(duì)數(shù)生長(zhǎng)的細(xì)胞,重懸后細(xì)胞密度為105/mL,取500 μL加入Transwell上室,下室加入750 μL含30% FBS的培養(yǎng)液作為趨化因子,培養(yǎng)48 h后取出小室,用棉拭子輕輕拭去小室內(nèi)非侵襲細(xì)胞,滴2~3滴Giemsa染色液染色3~5 min后,沖洗、晾干、觀察并拍照,每片膜隨機(jī)計(jì)數(shù)9個(gè)視野內(nèi)的穿膜細(xì)胞數(shù),計(jì)算平均值,每組設(shè)3個(gè)復(fù)孔。
1.4.5 Western blot法檢測(cè)SKOV-3細(xì)胞E-cadherin的蛋白表達(dá) 實(shí)驗(yàn)方法同“1.4.3”中的Western blot實(shí)驗(yàn)。
1.5 統(tǒng)計(jì)學(xué)方法
所有數(shù)據(jù)采用SPSS 13.0軟件進(jìn)行統(tǒng)計(jì)分析,計(jì)量資料以均數(shù)±標(biāo)準(zhǔn)差(x±s)表示,采用t檢驗(yàn)。以P < 0.05為差異有統(tǒng)計(jì)學(xué)意義。endprint
中國(guó)醫(yī)藥導(dǎo)報(bào)2017年30期